PRNewsWire · JNJ · November 7, 2026

Johnson & Johnson announces ICOTYDE® (icotrokinra) delivers significant improvement in psoriatic arthritis disease activity among biologic-naive patients with once-daily targeted oral peptide

Get the app for more

Explore stock news, insights and company research.